To improve cardiovascular outcomes, current guidelines encourage the use of GLP-1 receptor agonists and SGLT2 inhibitors in subjects with T2DM as well as SGLT2 inhibitors for the treatment of heart failure with the highest level of recommendation (Class I) [7, 58]. In subjects with T2DM and mild or moderate CKD, treatment with GLP-1 receptor agonists or SGLT2 inhibitors should be initiated, if therapy additional to metformin is required [58]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.